Today's clinical trials
are tomorrow's
treatment options.
SCRI.com
About SCRI
Sarah Cannon Research Institute (SCRI) is one of the world's
leading oncology research organizations conducting community-
based clinical trials. Focused on advancing therapies for patients
over the last three decades, SCRI is a leader in drug development.
It has conducted more than 750 first-in-human clinical trials since
its inception and contributed to pivotal research that has led
to the majority of new cancer therapies approved by the FDA
today. SCRI's research network brings together more than 1,300
physicians who are actively accruing patients to clinical trials at
more than 250 locations in 24 states across the U.S.
Research Physicians
across the
SCRI network
SCRI provides access to clinical trials at more than
250 locations in 24 states across the U.S.
RGB_SCRI Footprint Map_Monochromatic_Version 1.7
First-in-human
clinical trials since its
inception
1,300+
750+
0701/24SCM001/R10-CMYK
